Dubai’s Diginova to launch Biovista’s “AI Health Shield” in MENA and Asia

Diginova CEO, Sarper Tanli explained: "Biovista Personalized Medicine helps us deliver high quality-analytics to our consumers for any real-world clinical scenarios they may be facing. We see the AI Health Shield as a real disruptor in the delivery of data-driven healthcare services."

Aris Persidis, Biovista Personalized Medicine’s Managing Director added: "We see this deal as generating potentially over $5 billion in new AI-driven service revenues over its current iteration and lifetime, helping us continue to engineer better healthcare for everybody’s future."

THE LARGER CONTEXT

As explained by Biovista, its AI Health Shield compares a patient’s current diagnosis and treatment programme against "the many millions of evidence-based research reports published annually in scientific journals."

It then uses a personalised approach to recommend "either extensions or replacements of the standard of care when the latter fails."

The type of augmented intelligence-supported analytics can help physicians proactively adjust treatment plans and medications.

ON THE RECORD

The "next generation" augmented intelligence solution is reportedly being delivered to over 250 million patients in the Middle East and North Africa, and Asia territories.

A subsidiary of the US-based Biovista has teamed up with a UAE health solutions provider to deliver a "next generation" augmented intelligence solution to over 250 million patients in the Middle East and North Africa (MENA) and Asia territories.

Dubai’s Diginova Health Solutions is working with Biovista Personalized Medicine to offer its "AI Health Shield" in the region, in a deal that could generate over $5 billion (€4.3bn) in revenue.

Biovista claims that consumers of the solution will include "doctors, patients, their family caregivers, and national/regional health systems."

"We are excited to partner with Diginova on bringing our AI Health Shield to a major part of the world," said Persidis. "Diginova is excellent at integrating the right health solutions for patients and doctors and has an innovation-led vision for the future of healthcare that is aligned with ours."

Tanli added: "Outside of cancer, there were no AI-based solutions that could deeply understand patient data, including the use of data to understand existing therapies versus unanticipated ones, until the arrival of Biovista Personalized Medicine’s AI Health Shield."

Diginova CEO, Sarper Tanli explained: "Biovista Personalized Medicine helps us deliver high quality-analytics to our consumers for any real-world clinical scenarios they may be facing. We see the AI Health Shield as a real disruptor in the delivery of data-driven healthcare services."

Aris Persidis, Biovista Personalized Medicine’s Managing Director added: "We see this deal as generating potentially over $5 billion in new AI-driven service revenues over its current iteration and lifetime, helping us continue to engineer better healthcare for everybody’s future."

THE LARGER CONTEXT

As explained by Biovista, its AI Health Shield compares a patient’s current diagnosis and treatment programme against "the many millions of evidence-based research reports published annually in scientific journals."

It then uses a personalised approach to recommend "either extensions or replacements of the standard of care when the latter fails."

The type of augmented intelligence-supported analytics can help physicians proactively adjust treatment plans and medications.

Exclusive Article by Lindsey Patterson at Emrindustry